Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Altimmune stock
Learn how to easily invest in Altimmune stock.
Altimmune Inc is a biotechnology business based in the US. Altimmune shares (ALT) are listed on the NASDAQ and all prices are listed in US Dollars. Altimmune employs 43 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Altimmune
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ALT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Altimmune stock price (NASDAQ: ALT)Use our graph to track the performance of ALT stocks over time.
Altimmune shares at a glance
|Latest market close||$7.84|
|52-week range||$7.35 - $24.61|
|50-day moving average||$9.64|
|200-day moving average||$11.95|
|Wall St. target price||$31.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.11|
Buy Altimmune shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Altimmune stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Altimmune price performance over time
|1 week (2022-01-10)||-4.04%|
|1 month (2021-12-17)||-16.24%|
|3 months (2021-10-15)||-34.72%|
|6 months (2021-07-17)||-16.06%|
|1 year (2021-01-15)||-39.37%|
|2 years (2020-01-17)||326.09%|
|3 years (2019-01-17)||152.90%|
|5 years (2017-01-17)||33.5|
|Revenue TTM||$3.4 million|
|Gross profit TTM||$-25,324,291|
|Return on assets TTM||-21.31%|
|Return on equity TTM||-40.99%|
|Market capitalisation||$311.6 million|
TTM: trailing 12 months
Altimmune share dividends
We're not expecting Altimmune to pay a dividend over the next 12 months.
Have Altimmune's shares ever split?
Altimmune's shares were split on a 1:30 basis on 13 September 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Altimmune shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Altimmune shares which in turn could have impacted Altimmune's share price.
Altimmune share price volatility
Over the last 12 months, Altimmune's shares have ranged in value from as little as $7.35 up to $24.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is 1.3573. This would suggest that Altimmune's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Altimmune, Inc. , a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company develops T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase 1/2 clinical trials to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate for seasonal and pandemic use. It also focuses on developing pemvidutide, a next generation peptide therapeutics for non-alcoholic steatohepatitis; and HepTcell, an immunotherapeutic product candidate that is in Phase 2 studies for patients chronically infected with the hepatitis B virus. The company is headquartered in Gaithersburg, Maryland. .
Altimmune in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Altimmune Inc Shares Near 52-Week Low - Market Mover
Frequently asked questionsWhat percentage of Altimmune is owned by insiders or institutions?
Currently 5.923% of Altimmune shares are held by insiders and 84.844% by institutions. How many people work for Altimmune?
Latest data suggests 43 work at Altimmune. When does the fiscal year end for Altimmune?
Altimmune's fiscal year ends in December. Where is Altimmune based?
Altimmune's address is: 910 Clopper Road, Gaithersburg, MD, United States, 20878 What is Altimmune's ISIN number?
Altimmune's international securities identification number is: US02155H2004 What is Altimmune's CUSIP number?
Altimmune's Committee on Uniform Securities Identification Procedures number is: 02155H101
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
How to buy HeartCore Enterprises (HTCR) stock when it goes public
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Ask an Expert